PHF3 Inhibitors

Chemical inhibitors of PHF3 include a diverse set of compounds that target various biological pathways and processes to achieve functional inhibition of the protein. Okadaic Acid, for instance, maintains PHF3 in a hyperphosphorylated state by inhibiting protein phosphatases PP1 and PP2A, which would normally dephosphorylate PHF3. This hyperphosphorylation can hinder the functional roles of PHF3. Similarly, MG-132 acts by inhibiting the proteasome pathway, preventing the degradation of ubiquitinated proteins, potentially leading to an accumulation of misfolded proteins that sequester PHF3 in non-functional complexes. Trichostatin A and SAHA (Vorinostat), both HDAC inhibitors, increase acetylation of histones, which can disrupt PHF3's interaction with chromatin, as such interactions often depend on the acetylation status of histones.

Furthermore, 5-Azacytidine and Mithramycin A can interfere with the chromatin-associated functions of PHF3 by altering DNA methylation patterns and binding to DNA, respectively, thereby imposing steric or allosteric constraints on PHF3's ability to modulate gene expression. Alpha-Amanitin directly inhibits RNA polymerase II, affecting the transcriptional landscape in which PHF3 operates. Compounds like I-CBP112 and JQ1, which target BET bromodomain proteins, can indirectly influence the transcriptional networks involving PHF3, leading to a reduction in PHF3's regulatory functions. Pladienolide B, by inhibiting the spliceosome, disrupts RNA splicing processes where PHF3 is implicated, while PF-477736's inhibition of Chk1 can broadly affect cell cycle-regulated processes that involve PHF3. Lastly, UNC0638 targets histone methyltransferases G9a and GLP, altering histone methylation and potentially disrupting PHF3's interactions with these epigenetic markers, which can inhibit PHF3's chromatin-related activities.